Olympus Launches VISERA S, a New Imaging Platform

▴ Olympus
Supporting patient comfort, improved diagnostics, and streamlined workflow, available in Europe, parts of Asia and Oceania

TOKYO, Sept 30, 2024 - (JCN Newswire) - Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, today announced the launch of VISERA S1, the all-in-one imaging platform with stroboscopy. The new video platform integrates advanced diagnostic capabilities, including NBI (Narrow Band Imaging) technology2, and forms part of the expanding Ear, Nose and Throat (ENT) solution from Olympus. The company will first launch VISERA S from September 2024 in Europe and parts of Asia and Oceania. VISERA S will later be introduced in other regions after product registration has been approved by the local regulatory bodies.

Designed to help improve ENT diagnostic efficiency and patient experience, VISERA S offers an integrated video diagnosis system that brings NBI to a range of patient settings, from outpatient offices to private practices. With VISERA S, the clinician can switch between white light, NBI and stroboscopy capabilities and use the sharp HD quality visualization to detect, characterize and treat ENT disease.

  • An all-in-one platform with NBI and advanced visualization

VISERA S, with its improved color resolution, depth of field and minimized noise, is expected to improve the contrast and visibility of vascular structures and mucosa.

  • Integrated model with video system center and multiple light sources

In previous models, the video system and strobe light source were separated, but VISERA S integrates them into a single unit. This allows switching between white light mode, NBI and stroboscopy modes at the touch of a button, which is expected to improve operability.

  • Expanded compatibility

Enhancing Olympus’ commitment to continuous diagnostic and patient-centered innovation, VISERA S supports a HD camera head, which provides higher image quality than the legacy video platform. VISERA S is also highly adaptable by being compatible with other Olympus scopes, camera heads, monitors and other existing video equipment.

  • Streamline and simplify patient care

VISERA S is engineered to reduce effort and improve patient experience without complexity. While previous models could only store still images, the new imaging platform can store higher-quality still images and record video, capturing a comprehensive procedural record and contributing to comprehensive reporting.

Comment from Martijn Koster, Global ENT Business Unit Leader at Olympus

“VISERA S brings the power of early, patient-friendly diagnosis to the office, outpatient and private practice ENT care settings. By listening and innovating around the needs of our customers and their patients, we envision that the variety of diagnostic tools on the VISERA S can potentially diagnose disease earlier in the patient care pathway. The VISERA S will help ENT physicians deliver next-generation diagnostic imaging that advances their efforts to save lives through earlier diagnosis.”

1 This product is also applicable to urology and obstetrics and gynecology.
2 NBI (Narrow band imaging) is an imaging technique for examining features such as the small blood vessels in mucosa and the surface patterns. NBI highlights tissue by illuminating it with two narrow bands (wavelengths) of light that are absorbed by the hemoglobin in blood without making use of a fluorescence dye.

About Olympus

At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global X account: @Olympus_Corp.

Media contact:
Mail: Global-Public_Relations@olympus.com 

Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Healthcare Trends in 2026: What India's Doctors, Hospitals, and Patients Need to KnowJuly 18, 2026
Monsoon Health Problems in India: Understanding the Risks, Symptoms, and PreventionJuly 18, 2026
Fortis Escorts Faridabad Launches Faridabad’s First Comprehensive Lung Failure Clinic for Advanced Respiratory and Transplant CareJuly 17, 2026
What Seemed Like Persistent Gas Turned Out To Be A 30-cm Rare Cancer Occupying Most Of Her AbdomenJuly 17, 2026
Kidney Stone Prevention Initiative Unites More Than 8,200 Doctors Across India, Earns Asia Book of Records RecognitionJuly 17, 2026
Moscow radiologists introduce AI tool for hip dysplasia diagnosisJuly 17, 2026
Sharrp Ventures leads 100 CR investment in Naturis Cosmetics’ first institutional funding roundJuly 17, 2026
Eugenix Challenges Hair Loss Stigma With Nationwide 'I Chose Transformation' Campaign Featuring Boney KapoorJuly 17, 2026
How Artificial Intelligence is Reshaping Preventive Healthcare Through Earlier Detection and Smarter Clinical InsightsJuly 17, 2026
Five Common Myths About Children's Urinary Problems That Parents Should Stop BelievingJuly 17, 2026
Robotics in Surgery: How Robot-Assisted Procedures Are Transforming Healthcare in IndiaJuly 17, 2026
Wearable Health Devices: How Smart Technology Is Changing Healthcare in IndiaJuly 17, 2026
Sankara Eye Hospitals Successfully Hosts 20th Annual VISION 2020 India Conference, Celebrating 50 Years of the Sankara MovementJuly 16, 2026
Manipal Hospital Bhubaneswar Successfully Treats Rare Brain Injury Caused by Post-Traumatic Workplace AccidentJuly 16, 2026
Immuneel Therapeutics and Tata Memorial Centre Sign Strategic MoU to Advance Cell and Gene Therapy Research in India July 16, 2026
Breast Cancer Early Warning Signs: What Every Woman in India Needs to KnowJuly 16, 2026
HbA1c Test Explained: What It Measures, Normal Range, and Why It Matters for IndiansJuly 16, 2026
Not Just Weight Loss: How Bariatric Surgery Improves Diabetes, PCOS, and Thyroid-Related Health ChallengesJuly 15, 2026
Leiutis Pharmaceuticals announces CDSCO approval for Global-First Synthetic CBD Therapy for Mild to Moderate Anxiety DisordersJuly 15, 2026
Dr Agarwals Institute of Optometry and SASTRA University Jointly Launch Optometry ProgrammeJuly 15, 2026